What’s The Risk?” – New article about tCSM by DZS to appear in International Clinical Trials journal
Recently, Greg Ambra and Jean Battikha collaborated on an article that will be featured in this month’s International Clinical Trials titled, “What’s The Risk?”. The article features a novel scientific approach to identifying clinical trial data risk for small companies or companies that are resource constrained – targeted central statistical monitoring (tCSM).
DZS has been piloting this approach over the past year. Using a combination of pre-defined KRIs and other potential indicators that can be dynamically identified through targeted statistical review during the study, companies can achieve significant insight into study data. We will continue to publish the advantages and disadvantages including the potential cost-savings when combined with other approaches including risk-based monitoring (RBM).
This article is taken from International Clinical Trials November 2016, pages 17-19. © Samedan Ltd.ict-november-2016-p17-19